MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

MannKind Corporation announced new clinical data for Furoscix ReadyFlow, an autoinjector delivering IV-equivalent diuretic therapy for heart failure and chronic kidney disease. Presented at the HFSA 2026 Annual Scientific Meeting, the data demonstrates comparable urine output to IV furosemide, consistent bioavailability across injection sites, and seamless transition capabilities from the previous On-body Infusor formulation. The product received FDA approval in July 2026 and is designed to enable earlier outpatient intervention for fluid overload management.